ArticleAnnals of the rheumatic diseases2023
Risk factors for serious infections in ANCA-associated vasculitis.
Article in Annals of the rheumatic diseases, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 52 citations in OpenAlex.
- Cotrimoxazole for infection prevention in glomerulonephritis treated with rituximab: a randomized controlled trial.BMC medicine · 2025Trial
- Bactrim Efficacy in Preventing Infections in Glomerular Diseases Receiving Rituximab.Kidney medicine · 2026Article
- Development and validation of a risk score for serious infection in patients with rheumatic diseases receiving prolonged high-dose glucocorticoids.Arthritis research & therapy · 2026Article
- Proceedings of the 2Mediterranean journal of rheumatology · 2026Article
- The predictive value of baseline systemic inflammation response index and systemic immune-inflammation index for the risk of infection within 6 months following initial immunosuppressive treatment in patients with ANCA-associated vasculitis.Frontiers in immunology · 2026Article
- Understanding the burden of ANCA-associated vasculitis.Rheumatology (Oxford, England) · 2026Review
- Hypogammaglobulinaemia in patients with ANCA-associated vasculitis treated with rituximab.Frontiers in medicine · 2026Article
- Trimethoprim-sulfamethoxazole and the risk of early severe infection in elderly-onset myeloperoxidase-antineutrophil cytoplasmic antibody-associated vasculitis.BMC nephrology · 2025Observational
- Challenges in the diagnosis, classification and prognosis of ANCA-associated vasculitis.Nature reviews. Rheumatology · 2025Review
- Time-Dependent Effect of Prophylactic Trimethoprim-Sulfamethoxazole on the Incidence of Serious Infections in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A Target Trial Emulation Study.Arthritis & rheumatology (Hoboken, N.J.) · 2025Observational
- B-Cell Depletion in Glomerular and Autoimmune Diseases: Too Much of a Good Thing?Kidney international reports · 2025Article
- Relapses and serious adverse events during rituximab maintenance therapy in ANCA-associated vasculitis: a multicentre retrospective study.Rheumatology (Oxford, England) · 2025Article
- Trimethoprim sulfamethoxazole prophylaxis and serious infections in granulomatosis with polyangiitis treated with rituximab.Rheumatology (Oxford, England) · 2025Article
- Safety of Avacopan for the Treatment of Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: Combined Data From Three Clinical Trials.ACR open rheumatology · 2025Article
- Review
- Top ten tips in managing ANCA vasculitis.Clinical kidney journal · 2025Review
- Risk of pulmonary fungal infections associated with biologics: a FAERS database disproportionality analysis.Frontiers in immunology · 2025Article
- [Update on treatment of ANCA-associated vasculitis].Zeitschrift fur Rheumatologie · 2024Review
- Anti-Neutrophil Cytoplasmic Antibody-Associated Vasculitis in China: Epidemiology, Management, Prognosis, and Outlook.Kidney diseases (Basel, Switzerland) · 2024Review
- Current perspective on infections and mitigation strategies in primary systemic vasculitis.Current rheumatology reports · 2024Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 10 institutions in 5 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesSevere infections contribute to morbidity and mortality in antineutrophil cytoplasm antibody-associated vasculitis (AAV). This study aimed to identify risk factors associated with severe infections in participants of the Rituximab versus Cyclophosphamide for ANCA-Associated Vasculitis (RAVE) trial.
methodsData on 197 patients recruited into the RAVE trial were analysed. Participants received either rituximab (RTX) or cyclophosphamide (CYC), followed by azathioprine (AZA). Clinical and laboratory data of patients with and without severe infections (≥grade 3, according to the Common Terminology Criteria for Adverse Events version 3.0) were compared. Risk factors for severe infections were investigated using Cox-regression models.
resultsEighteen of 22 (82%) severe infections occurred within 6 months after trial entry, most commonly respiratory tract infections (15/22, 68%). At baseline, lower absolute numbers of CD19+ cells were observed in patients with severe infections either receiving RTX or CYC/AZA at baseline, while CD5+B and CD3+T cells did not differ between groups. In Cox-regression analysis, higher baseline serum immunoglobulin M levels were associated with the risk of severe infections, whereby a higher baseline total CD19+B cell number and prophylaxis against
conclusionsThe use of low-dose TMP/SMX is associated with reduced risk of severe infections in patients with AAV treated with either RTX or CYC/AZA. Reduced B cell subpopulations at start of treatment might be a useful correlate of reduced immunocompetence.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.